Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. 110 (August 2016) (2016) 205–215]
Title:
Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. 110 (August 2016) (2016) 205–215]
Author:
Gómez-Cañas, M. Morales, P. García-Toscano, L. Navarrete, C. Muñoz, E. Jagerovic, N. Fernández-Ruiz, J. García-Arencibia, M. Pazos, M.R.